Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: A pharmacokinetic-pharmacodynamic study

British Journal of Anaesthesia

Volumn 103, Issue 3, 2009, Pages 420-427

  Ginosar, Y ^a   Davidson, E M ^a   Meroz, Y ^a   Blotnick, S ^a   Shacham, M ^a   Caraco, Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Analgesia, patient controlled; Genetic factors; Pharmacodynamics; Pharmacokinetics, alfentanil; Receptors, opioid

Indexed keywords

ALFENTANIL; MU OPIATE RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SELF ADMINISTRATION; GENE FREQUENCY; GENETIC CODE; GENOTYPE; HUMAN; LITHOTRIPSY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 69049108798     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep192     Document Type: Article

References (21)

1. Caraco Y. Genes and the response to drugs. N Engl J Med 2004; 351: 2867-2869
2. Mayer P, Höllt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006; 16: 1-7
3. Belfer I, Wu T, Kingman A, Krishnaraju RK, Goldman D, Max MB. Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology 2004; 100: 1562-1572 (Pubitemid 38684137)
4. Max MB, Stewart WF. The molecular epidemiology of pain: a new discipline for drug discovery. Nat Rev Drug Discov 2008; 7: 647-658
5. Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003; 81: 154-167 (Pubitemid 36470182)
6. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-9613 (Pubitemid 28506279)
7. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol 2000; 410: 249-268 (Pubitemid 32008148)
8. Li T, Liu X, Zhu ZH, et al. Association analysis of polymorphisms in the mu opioid gene and heroin abuse in Chinese subjects. Addict Biol 2000; 5: 181-186 (Pubitemid 30229462)
9. Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005; 6: 159-167 (Pubitemid 40365019)
10. Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006; 103: 1011-1017 (Pubitemid 44576714)
11. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008; 139: 5-14
12. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107-121 (Pubitemid 36158492)
13. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16: 625-636 (Pubitemid 44223074)
14. Oertel BG, Preibisch C, Wallenhorst T, et al. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther 2008; 83: 577-588
15. Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9 (Pubitemid 34112237)
16. Chou WY, Yang LC, Lu HF, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50: 787-792 (Pubitemid 44034227)
17. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105: 334-337 (Pubitemid 44148178)
18. Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109: 520-526
19. Reyes-Gibby CC, Shete S, Rakvå g T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130: 25-30 (Pubitemid 46850782)
20. Lemmens HJM, Burm AGL, Bovill JG, Hennis PJ, Gladines MPRR. Pharmacodynamics of alfentanil: the role of plasma protein binding. Anesthesiology 1992; 76: 65-70
21. Avramov MN, White PF. Use of alfentanil and propofol for outpatient monitored anesthesia care: determining the optimal dosing regimen. Anesth Analg 1997; 85: 566-572